Riboxin
Riboxin
- Active ingredient (INN): inosine.
- ATH code: C01EB
- Pharmacotherapeutic group:
- means for the correction of metabolic processes.
Pharmacological properties
Riboxin belongs to the group of anabolic drugs that stimulate metabolic processes. Derivative (nucleoside) of purine, precursor of adenosine triphosphate (ATP). It has a positive effect on metabolic processes in the myocardium - it increases the activity of a number of Krebs cycle enzymes and improves energy balance, increases the strength of heart contractions and contributes to a more complete relaxation of the myocardium in diastole (binds calcium ions that have entered the cytoplasm at the time of excitation), improves blood supply to tissues, in including coronary circulation, reduces platelet aggregation, activates tissue regeneration (especially myocardium and mucous membrane of the gastrointestinal tract). Increases the pharmacological protection of the kidneys subjected to ischemia during surgery. Substrate stimulates the synthesis of adenyl nucleotides.
Pharmacokinetics
After intravenous administration, it is distributed in the tissues of the body. It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.
Indications for use
Comprehensive treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, myocardial dystrophy after infectious diseases. It is also indicated for liver diseases (hepatitis, cirrhosis, fatty degeneration of the liver), treatment of urocoproporphyria. In addition, riboxin is used during operations on an isolated kidney as a means of pharmacological protection, when the blood circulation of the operated organ is temporarily turned off.
